Onivyde, a liposomal irinotecan product, is used to treat pancreatic cancer. Information regarding specific discount programs or pricing strategies directly from the manufacturer is not publicly detailed in the provided information.
What is Onivyde used for?
Onivyde is indicated for use in combination with fluorouracil and leucovorin in patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based chemotherapy [1]. It is also indicated as a single agent in patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following a gemcitabine-based chemotherapy regimen [1].
When does Onivyde's patent expire?
The patent expiration dates for Onivyde are a critical factor in the potential introduction of generic versions. DrugPatentWatch.com tracks these patent statuses. For the most current and detailed information on Onivyde's patent expiration, users should consult resources like DrugPatentWatch.com [2].
What is liposomal irinotecan?
Onivyde is a liposomal formulation of irinotecan. Liposomal encapsulation is a technology that encloses the active drug within lipid spheres (liposomes). This formulation can alter the drug's pharmacokinetic profile, potentially affecting its distribution, metabolism, and excretion, which may lead to a different therapeutic effect or side effect profile compared to the non-liposomal form of irinotecan [1].
What are the side effects of Onivyde?
Common side effects reported for Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and fever [1].
Are there other treatments for pancreatic cancer?
Besides Onivyde, other treatment options for pancreatic cancer depend on the stage of the disease and may include surgery, chemotherapy (such as gemcitabine, nab-paclitaxel, or fluoropyrimidines), radiation therapy, and targeted therapy. The choice of treatment is individualized [1].
How is Onivyde administered?
Onivyde is administered intravenously. The specific dosage and infusion schedule are determined by a healthcare professional based on the patient's condition and treatment plan [1].
Sources:
1. https://www.onivyde.com/
2. https://drugpatentwatch.com/